Immunicum - ilixadencel in MERECA Phase II - results soon ! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunicum - ilixadencel in MERECA Phase II - results soon !

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: loparn	8/20/2019 1:55:38 PM
	of 17

Immunicum held a very informative company presentation in Stockholm today, mostly dealing with their unique immune primer ilixadencel. I recommend watching it here. redeye.solidtango.com The Phase II RCC MERECA study results will be presented within 2 weeks. It could be a sensation in immuno oncology if the Phase I/II outcome will be repeated in MERECA which in the former case was for example an 18 month overall survival rate of 73 % compared to historical reference data of around 45 % for a group of patients with MSKCC high risk and MSKCC intermediate risk. Of course I am a stockholder... infoom.se

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next